{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-014881","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2022-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.438966+00:00","generated_at":"2026-06-25T09:08:04.222672+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ChromaDex forms JV to commercialize Tru Niagen in China; gets 71% voting interest","bullets":["JV partners Crystal Lake, Pioneer Idea, Taikuk contribute $1.8M, $1.2M, $1.0M total $4M into the JV.","ChromaDex holds 71% voting interest, appoints 3 of 5 directors; Taikuk gets 11% non-voting interest after $1M fee.","JV to commercialize Tru Niagen and other NR products in Mainland China (excl. HK, Macau, Taiwan) under 20-year term.","Health food (Blue Hat) registration with China SAMR required for broad distribution; must be obtained within 24 months of closing.","JV expects to enter distribution agreement with Sinopharm Xingsha upon regulatory approval; closing targeted by Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-014881","json":"https://secwatch.observer/filing/0001628280-22-014881.json","markdown":"https://secwatch.observer/filing/0001628280-22-014881.md","text":"https://secwatch.observer/filing/0001628280-22-014881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022014881/0001628280-22-014881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022014881/cdxc-20220519.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T09:08:04.222672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}